Recent News

• 06.11.2026 - Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
• 06.09.2026 - Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
• 05.27.2026 - Palisade Bio to Participate in the Jefferies Global Healthcare Conference
• 05.12.2026 - Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
• 05.05.2026 - Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Recent Filings

• 06.10.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.27.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.21.2026 - EFFECT Notice of Effectiveness
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - 8-K Current report
• 05.12.2026 - EX-99.1 EX-99.1